HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing
MWN-AI** Summary
HCW Biologics Inc. (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing immunotherapies for age-related diseases, expressed its congratulations to Wugen, Inc. on successfully closing a $115 million equity financing round. This financing was primarily led by Fidelity Management & Research Company, with additional participation from prominent investors such as RiverVest Venture Partners, Lightchain Capital, and Abingworth.
As a strategic partner and minority equity stakeholder in Wugen, HCW Biologics received its interest through a license agreement signed in 2020. Since then, the collaboration has generated $16.2 million in revenue for HCW, stemming from license fees and clinical material sales to support Wugen's clinical trials.
Dr. Hing C. Wong, CEO of HCW Biologics, highlighted the significant support from a high-caliber group of institutional investors backing Wugen's advancement in next-generation allogeneic CAR-T cell therapies, emphasizing optimism about the company's future developments.
Wugen, headquartered in St. Louis, Missouri, is advancing innovative off-the-shelf cell therapies designed from healthy donor cells to tackle critical unmet needs in hematologic malignancies. Its proprietary CAR-T platform is tailored for both scale and efficiency, ensuring rapid delivery of vital treatments.
HCW Biologics aims to transform the treatment landscape for diseases exacerbated by chronic inflammation through its proprietary drug discovery technologies. These platforms, including the TRBC platform, facilitate the development of diverse immunotherapeutics targeting various diseases, including cancer and autoimmune disorders.
The successful funding for Wugen not only represents a milestone for the company but also significantly boosts HCW Biologics' position, reinforcing its commitment to discovering novel therapies for improved patient outcomes.
MWN-AI** Analysis
HCW Biologics Inc. (NASDAQ: HCWB), a clinical-stage biopharmaceutical company, is riding the coattails of Wugen, Inc.’s recent successful equity financing, which raised $115 million. As a shareholder, HCW’s minority stake positions it favorably for potential revenue boosts as Wugen advances its pioneering off-the-shelf CAR-T cell therapies for hematologic malignancies. This equity financing, led by Fidelity Management and Research Company, enhances Wugen’s financial stability and development capability, signaling strong institutional confidence in its innovative pipeline.
For investors considering HCW Biologics, the company’s strategic alignment with Wugen presents a compelling narrative. HCW has recognized $16.2 million in revenues from its 2020 licensing agreement with Wugen, showcasing a successful monetization of its equity interest. The company's focus on developing novel immunotherapies to combat chronic inflammation aligns with growing market demands for innovative treatments targeting age-related diseases and cancer, enhancing its long-term investment appeal.
However, it’s important for potential investors to approach HCW Biologics with a cautious perspective. Biopharmaceuticals are characterized by high volatility and inherent risks, especially for clinical-stage companies. The success of HCW's own product candidates, particularly the proprietary HCW9302 and the versatile TRBC platform, remains to be further validated through preclinical and clinical trials.
Additionally, broader market trends, regulatory pressures, and capital requirements for ongoing development can affect volatility. Therefore, investors should consider diversifying their portfolios while monitoring HCW Biologics' advancements closely, particularly as Wugen continues to execute its operational strategy post-financing. Overall, HCW presents a nuanced opportunity, merging stability from Wugen with the potential for substantial upside as its innovative therapies progress.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Wugen closed a $115 million equity financing led by
Fidelity Management & Research Company
HCW Biologics holds a minority equity interest in Wugen
MIRAMAR, Fla., Sept. 18, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, congratulates Wugen, Inc. (“Wugen”) on its recently announced $115 million equity financing led by Fidelity Management & Research Company, with participation from RiverVest Venture Partners, Lightchain Capital, Abingworth, ICG, LYZZ Capital, Tybourne Capital Management, Aisling Capital Management, and other leading life sciences investors.
HCW Biologics holds a minority equity interest in Wugen which it received as a license fee for the 2020 Wugen Exclusive License Agreement. Since inception, the Company recognized $16.2 million of revenues under the license agreement derived from an upfront license fee, paid in cash and shares of Wugen common stock, and product sales for clinical material ordered by Wugen for its clinical trials.
Dr. Hing C. Wong, the Company’s Founder and CEO, stated, “As a shareholder of Wugen, we are excited to see a high-quality syndicate of institutional investors support Wugen’s continued development of their next generation of allogeneic, off-the-shelf CAR-T cell therapies.”
About HCW Biologics:
HCW Biologics Inc. (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing proprietary immunotherapies to treat diseases promoted by chronic inflammation, especially age-related and senescence-associated diseases. The Company’s immunotherapeutics represent a new class of drugs that it believes have the potential to fundamentally change the treatment of cancer and many other diseases and conditions that are promoted by chronic inflammation — and in doing so, improve patients’ quality of life and potentially extend longevity. Chronic inflammation, including inflammaging, is believed to be a significant contributing factor to senescence-associated diseases and conditions that diminish healthspan, including many types of cancer, autoimmune diseases, and neurodegenerative diseases, as well as many indications that impact quality-of-life that are not life-threatening. The Company’s lead product candidate, HCW9302, was developed using the Company’s legacy TOBI™ (Tissue factOr-Based fusIon) platform. The Company has created another drug discovery technology, the TRBC platform, which is not based on Tissue Factor. The TRBC platform has the capability to construct immunotherapeutics that not only activate and target immune responses but are also equipped with receptors that specifically target cancerous or infected cells. This platform is a versatile scaffold that enables the creation of multiple classes of immunotherapeutic compounds: Class I: Multi-Functional Immune Cell Stimulators; Class II: Second-Generation Immune Checkpoint Inhibitors; Class III: Multi-Specific Targeting Fusions and Enhanced Immune Cell Engagers. These novel immunotherapeutics are being developed for treatment of a wide range of disease indications, including oncology, autoimmune diseases, and improving quality of life conditions. The Company has constructed over 50 molecules using the TRBC platform. Further preclinical evaluation studies are currently being conducted for these molecules the Company has selected based on promising preclinical data. The Company has two licensing programs in which it has licensed exclusive rights for some of its proprietary molecules. See the Company Pipeline at https://hcwbiologics.com/pipeline/ .
About Wugen:
Wugen, Inc., headquartered in St. Louis, Missouri, Wugen, is a pivotal-stage American-born biotechnology company advancing the next generation of off-the-shelf cell therapies. Its allogeneic therapies are derived from healthy donor cells and are engineered to deliver robust anti-tumor activity. With its proprietary CAR-T platform, Wugen is addressing critical unmet needs in hematologic malignancies. Its US-based manufacturing is optimized for scale, consistency, and rapid deployment, enabling the delivery of transformative therapies to patients with speed and precision. For more information, please visit https://wugen.com/ .
Forward Looking Statements:
Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties that are described in the section titled “Risk Factors” in the annual report on Form 10-K filed with the United States Securities and Exchange Commission (the “SEC”) on March 28, 2025, the latest Form 10-Q filed with the SEC on August 18, 2025 and in other filings filed from time to time with the SEC.
Company Contact:
Rebecca Byam
CFO
HCW Biologics Inc.
rebeccabyam@hcwbiologics.com
FAQ**
How does HCW Biologics Inc. (HCWB) envision the potential impact of Wugen's recent $1million equity financing on its ongoing relationship and equity interest in Wugen?
What specific developments in Wugen's allogeneic CAR-T therapies could positively influence HCW Biologics Inc. (HCWB)'s revenue generation from its minority equity stake?
Given HCW Biologics Inc. (HCWB)'s focus on immunotherapies for chronic inflammation, how does it assess the synergy between its pipeline and Wugen's CAR-T therapies post this financing round?
How does HCW Biologics Inc. (HCWB) plan to leverage Wugen's advancements following the new financing to enhance its strategic positioning in the biopharmaceutical market?
**MWN-AI FAQ is based on asking OpenAI questions about HCW Biologics Inc. (NASDAQ: HCWB).
NASDAQ: HCWB
HCWB Trading
194.2% G/L:
$1.015 Last:
297,600,655 Volume:
$1.11 Open:
